Cross-talk Between Statins and PPARα in Cardiovascular Diseases: Clinical Evidence and Basic Mechanisms

This publication has 35 references indexed in Scilit:

• Statins Activate Peroxisome Proliferator-Activated Receptor γ Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase–Dependent Cyclooxygenase-2 Expression in Macrophages
  Circulation Research, 2007
• Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–α Activators
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2006
• PLEIOTROPIC EFFECTS OF STATINS
  Annual Review of Pharmacology and Toxicology, 2005
• Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol
  The American Journal of Cardiology, 2005
• Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
  The American Journal of Cardiology, 2005
• Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells
  Life Sciences, 2004
• Peroxisome Proliferator-Activated Receptors and Atherogenesis
  Circulation Research, 2004
• Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARα/RXRα and Decrease the Transactivation of NFκB
  Biochemical and Biophysical Research Communications, 2002
• Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I
  Journal of Clinical Investigation, 2001
• Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells
  Life Sciences, 2000